Form 4: Vyne Therapeutics CFO Tyler Zeronda Reports Stock Disposal for Tax Obligations

Sentiment:

SEC Form 4 Filing


Tyler Zeronda, CFO of Vyne Therapeutics, reports the disposal of 84 common stock shares to cover tax withholding requirements related to vesting restricted stock units.

Summary

  • On September 30, 2024, Tyler Zeronda, the Chief Financial Officer of Vyne Therapeutics Inc., disposed of 84 shares of common stock.
  • The transaction was executed to satisfy tax withholding requirements associated with the vesting of restricted stock units.
  • The shares were disposed of at a price of $1.88 per share.
  • Following the transaction, Zeronda directly owns 131,567 shares of Vyne Therapeutics Inc.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to stock transactions for tax purposes, indicating a neutral sentiment.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, like the CFO, engage in transactions involving the company's securities. These filings provide transparency to the market regarding insider activity.

Stakeholder Impact

  • The transaction has a minimal impact on shareholders as it involves a small number of shares disposed of for tax purposes.

Key Dates

DateDescription
09/30/2024Date of stock disposal transaction
10/02/2024Date of signature for the Form 4 filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.